Opening arguments began Thursday in the first of several thousand pending Vioxx cases. Though manufacturer Merck & Co.'s strategy is to defend the suits one by one, many can't help but see this trial as setting the tone for the rest of the litigation. Lead plaintiffs attorney Mark Lanier admits that, historically, plaintiffs lawyers lose the first few mass torts cases and learn from their mistakes. "General wisdom has it that I should lose," he says, "but I'm never one to bet on general wisdom."
Lawyers in First Vioxx Suit Battle Over Causation
July 15, 2005
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.